Oncology experts discuss the future of multi-cancer detection in Madrid

Februari 2, 2026

On February 9, OncoInv will host an exclusive expert meeting at Madrid Health Hub, bringing together leading voices in oncology to discuss the evolving role of multi-cancer early detection (MCED) in clinical practice.

MCED is entering a new phase. As the evidence base continues to mature, the central question for oncology systems is no longer whether MCED will become part of routine care, but how and when it can be responsibly integrated. This transition has implications that extend beyond technology alone, raising fundamental questions about clinical decision-making, patient pathways, and the organisation of oncology care.

To explore these challenges, OncoInv is convening a high-level panel of four key opinion leaders in oncology. The discussion will focus on the practical and systemic dimensions of MCED adoption, including clinical validation, ethical considerations, health system readiness, and implementation across existing care models.

Rather than approaching MCED as a standalone innovation, the session is designed as a strategic exchange on how emerging evidence can be translated into sustainable clinical practice. By facilitating an open and informed dialogue among experts, the meeting aims to support more thoughtful decision-making around the future integration of MCED within oncology pathways.

With this initiative, OncoInv reinforces its role as a knowledge partner and convener in early cancer detection, contributing to the responsible evolution of oncology care through evidence-based discussion and cross-disciplinary insight.

Click here for more information about the event

More news

Jesper Verhey appointed CEO to lead OncoInv's next phase of accelerating impact in early cancer detection

February 3rd, 2026

As of 1 February, Jesper Verhey MSc, has taken on the role of CEO of OncoInv. This step marks the next phase in the company’s development, building on the progress of recent years and placing responsible implementation and real-world evidence generation at the centre of its work...

Read more
The University of Costa Rica launches its multi-cancer detection program using the OncoSeek® test

January 15th, 2026

OncoInv collaborates with the Universidad de Costa Rica (UCR) to support the introduction of the OncoSeek® multi-cancer detection test in Costa Rica. Through this collaboration, the test is now available within a public academic and clinical setting, marking an important step in expanding access to advanced cancer detection technologies in the region...

Read more
New publication adds to growing evidence base for OncoSeek® in multi-cancer early detection

December 17th, 2025

A recently published study in npj Precision Oncology adds further depth to the growing body of scientific evidence around multi-cancer early detection and the performance of OncoSeek®...

Read more